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Introduction
The genus Bordetella contains several pathogenic species
generally associated with upper respiratory tract infections in
warm-blooded animals. Bordetella pertussis is the etiologic agent
of whooping cough, a disease that still causes approximately
300,000 deaths worldwide and is currently considered to be
reemerging, even in the industrialized world. Bordetella
parapertussis causes a mild whooping cough-like syndrome,
whereas Bordetella bronchiseptica is isolated rarely from humans,
essentially only from severely immunocompromised individuals.
B. pertussis and B. parapertussis are typical human pathogens,
although B. parapertussis has also been found in sheep [48].
In contrast, B. bronchiseptica is found in many mammalian
species, in which it generally remains pathogenically silent.
However, it is known to cause kennel cough in dogs and atrophic
rhinitis in pigs. These three Bordetella species have very similar
DNA sequences, although the chromosomes of B. parapertussis
and B. bronchiseptica are approximately 1 Mb larger than that
of B. pertussis [59]. The more distantly related Bordetella avium
causes respiratory tract infections in birds. This microorganism
appears to be more closely related to two other Bordetella species
recently isolated from humans, Bordetella hinzii [11] and
Bordetella holmesii [67]. 
Our understanding of the molecular mechanisms of
Bordetella pathogenesis is increasing, especially for B. pertussis.
Many of its virulence factors have been identified, their genes
cloned and sequenced and their structure-function relationship,
biogenesis and genetic regulation intensively studied in many
different laboratories around the world. Since its discovery in
1906 by Bordet and Gengou [5], B. pertussis has classically
been considered an extracellular pathogen. However, during
the past decade it has been realized that it can also survive
within a variety of eukaryotic cell types [13], including
macrophages and epithelial cells. The physiopathological
significance of the intracellular survival of B. pertussis has not
yet been clearly determined. 
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Molecular aspects of Bordetella
pertussis pathogenesis
Summary The molecular mechanisms of Bordetella virulence are now well
understood, and many virulence factors have been identified and characterized at
the molecular level. These virulence factors can be grouped into two major categories:
adhesins, such as filamentous hemagglutinin, pertactin and fimbriae, and toxins,
such as pertussis toxin, adenylate cyclase, dermonecrotic toxin and tracheal cytotoxin.
The production of most virulence factors is coordinately regulated by a two-component
signal transduction system composed of the regulator BvgA and the sensor protein
BvgS. The adhesins and toxins act in concert to establish infection. Some adhesins
exert their effects synergically or are redundant functioning only in the absence of
another adhesin, illustrating the importance of adhesion in infection. Most virulence
factors are secreted into the culture supernatant or exposed at the surface of the
bacterial cell. A notable exception is dermonecrotic toxin, which remains 
in the cytoplasmic compartment of bacterial cells. Most virulence factors are produced
by all of the three major Bordetella species, B. pertussis, B. parapertussis and 
B. bronchiseptica. However, some, such as pertussis toxin and the tracheal colonization
factor, are only produced by B. pertussis. Our understanding of Bordetella virulence
at the molecular level has led to the development of new acellular vaccines against
whooping cough, and of genetically attenuated B. pertussis strains to be used as
recombinant live bacterial vaccine vectors for homologous and heterologous
protection. 
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The genetic regulation of B. pertussis
virulence genes
Phenotypic modulation and phase variation B. pertussis
virulence factors are typically divided into two main
categories: adhesins and toxins. Most are proteins, and the
expression of their structural genes is coordinately regulated
at the transcriptional level in response to environmental
signals. The virulence genes are not expressed at low
temperature or in the presence of MgSO4 or nicotinic acid,
whereas they are expressed at 37°C and in the absence of
MgSO4 and nicotinic acid. This reversible physiological
adaptation of B. pertussis has been termed phenotypic
modulation [30]. However, within a population of Bordetella
cells, irreversible loss of virulence factor production, even
at 37°C and in the absence of MgSO4 and nicotinic acid also
occasionally occurs, and has been termed phase variation
[62]. 
The BvgA/S two-component system The genetic locus
responsible for both phenotypic modulation and phase
variation is the bvg locus, consisting of at least two closely
linked genes, bvgA and bvgS [62]. These genes encode the
constituents of a two-component regulatory system. BvgA
is a typical transcriptional activator, containing an N-terminal
receiver domain and a C-terminal output domain with a
helix-turn-helix motif capable of binding its DNA target
sequences. BvgS is a sensor protein located in the inner
membrane of the organism. It contains a large periplasmic
domain, which is connected to a cytoplasmic domain by a
membrane-spanning and a linker region. Within the large
family of two-component sensor proteins, BvgS is unusual
in having a particularly large cytoplasmic region containing
several distinguishable subdomains. In addition to the usual
transmitter module with a conserved histidine residue and
an ATP-binding site, it contains a receiver module and a 
C-terminal subdomain with a second conserved histidine
residue of transmitter domains and a second ATP-binding
site. 
Signal transduction by the BvgA/S system occurs via a
succession of phosphotransfer reactions. At high temperature
and in the absence of MgSO4 and nicotinic acid, BvgS
autophosphorylates at the first conserved histidine residue
within the transmitter domain, using ATP as a phosphodonor.
The phosphate is then transferred from this histidine to an
aspartate from the receiver module within the cytoplasmic
domain of BvgS, and finally from this aspartate to the second
conserved histidine in the C-terminal subdomain of BvgS. From
this C-terminal subdomain, the phosphate group is then finally
transferred to the N-terminal receiver domain of BvgA.
Phosphorylation of BvgA increases the affinity of its output
domain for the target DNA sequences located within the
promoter regions of the virulence genes [8], which activates
the transcription of these genes. Interestingly, as found for many
other two-component systems, amplification of the signal occurs
via transcriptional auto-activation of the bvgA/S genes by
phosphorylated BvgA itself. 
The vag and vrg genes The BvgA/S system not only activates
a set of virulence genes, called vags (for virulence activated
genes) but may also repress the expression of another set of
genes, the vrgs (for virulence repressed genes). The repression
of at least some of these genes requires the expression of an
intermediate regulatory gene, bvgR, located directly
downstream from the bvgA and bvgS genes [42]. The
expression of bvgR is under the transcriptional control of
BvgA. In the virulent phase, when the BvgA/S system is
activated, both vags and bvgR are expressed, which in turn
represses the vrgs. In modulating conditions, (i.e. at 25°C or
in the presence of MgSO4 or nicotinic acid), the BvgA/S
system is inactivated, vags are not expressed and vrgs are
derepressed. The functional role of the vrgs in B. pertussis
is unknown. However, ectopic expression of these genes
results in a defect in tracheal colonization, at least in
laboratory animal models [1]. 
Adhesins
Of the various virulence factors B. pertussis produces under
the control of the BvgA/S system, a number of adhesins are
found at the surface of the organism, several of which have
been studied in some detail (Table 1). These include filamentous
hemagglutinin, fimbriae, also called agglutinogens, pertactin,
the serum-resistance protein Brk and the attachment factor Tcf. 
Filamentous hemagglutinin The best studied B. pertussis
adhesin is filamentous hemagglutinin (FHA). It is produced as
a 370 kDa precursor encoded by the fhaB gene, which is
located directly upstream from the bvg genes [39]. The FhaB
precursor undergoes N-terminal and C-terminal proteolytic
processing, resulting in the 220 kDa mature FHA [54]. The
structural model of mature FHA, based on high-resolution
electron microscopy and circular dichroism measurements, as
well as secondary structure predictions, is a filamentous
monomeric molecule approximately 50 nm long and folded
like a hairpin [40]. It has a rod-like shape with a diameter of 
4 nm, and contains at one extremity a globular structure formed
by the N-terminal and C-terminal ends of the molecule. It has
been suggested that 19-residue repeated motifs form an
elongated amphiphilic β-sheet structure, joining the N-terminal
and C-terminal moieties of the molecule by their hydrophobic
interfaces to form the rod-like structure. 
The N-terminal region of the precursor molecule contains
an unorthodox signal peptide [27], which is unusual in that it
is 71 residues long and consists of two parts. The first part, the
N-terminal extension, is homologous to the N-terminal
extremities of several other adhesin precursors from Gram-
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negative organisms. Its function is unknown. It is followed by
a sequence with the features of a typical signal peptide,
suggesting that the FHA precursor is transported through 
the cytoplasmic membrane by a classical Sec system. The 
N-terminal residue of mature FHA is pyroglutamate, a modified
glutamine residue, that has undergone posttranslational
cyclization by an unknown mechanism [32]. 
The N-proximal region of mature FHA is homologous to
a domain found in various hemolysins and other adhesins from
Gram-negative pathogens. This approximately 120 residue
domain is essential for the translocation of FHA through the
outer membrane. It contains very well conserved AN(P/S)NL
and NPNGI motifs, in which the asparagines play a particularly
important, though not yet defined role in FHA export [28]. 
The secretion of FHA requires an accessory protein located
in the outer membrane. This protein, FhaC, is homologous to
the accessory proteins involved in the secretion of the
hemolysins and adhesins of other microorganisms containing
an N-proximal domain homologous to FHA. It is likely that
the conserved domains of these proteins interact with the FhaC-
like accessory proteins during the course of transport through
the outer membrane. The fhaC gene lies downstream from the
fhaB gene, and the two genes are separated by three genes
involved in B. pertussis fimbrial biogenesis [69], indicating
that the production of FHA is closely coregulated with that
of the fimbriae. 
The secretion domain of FHA is followed by several repeats.
These repeats may be involved in the binding of FHA to sulfated
glycosaminoglycans (ligands for FHA) via which B. pertussis
may bind to epithelial cells [22]. In addition, an Arg-Gly-
Asp motif is located downstream from these repeats and has
been shown to be involved in the interaction of FHA with the
CR3 integrin on the surface of macrophages [53]. The hairpin
structure model suggest that the Arg-Gly-Asp sequence should
be located at one of the extremities of the rod. Finally, a third
region has been identified in FHA, downstream from the 
Arg-Gly-Asp sequence. This third region may be responsible
for the adhesion of FHA to galactose-containing glyco-
conjugates [50]. This region is also the immunodominant part
of the molecule [34]. 
The C-terminal portion of the FHA precursor is removed
during processing. Its role has not been clearly identified, but
it appears to be important for the secretion of full-length FHA,
but not for truncated FHA molecules, provided they contain
the secretion domain. It probably does not itself contain
secretion determinants, but has been suggested to act as an
intramolecular chaperone to prevent the premature folding of
FHA in the periplasm, which would hamper its transport
through the outer membrane [54]. 
FHA has long been considered to be the major B. pertussis
adhesin. However, it functions in conjunction with other
adhesins, such as the fimbriae, pertactin and even pertussis
toxin. Some of these adhesins may even substitute for FHA
or may be redundant, especially in strains lacking FHA.
During infection, in both humans and animal models, FHA
induces a strong antibody response, both systemically and
mucosally [61], and vaccination with purified FHA confers
protection against respiratory challenge in mice. For this
reason, FHA has been included in new, second-generation
vaccines against whooping cough [56]. FHA also has adjuvant
activity for antigens delivered with it by the nasal route [49].
These properties can be exploited to develop systems for
presenting heterologous antigens to the respiratory mucosa
[55]. 
The fimbriae B. pertussis produces fimbriae of two serotypes,
serotype 2 and serotype 3, composed of the major fimbrial
subunits Fim2 (22.5 kDa) and Fim3 (22 kDa) respectively.
The B. pertussis genome also harbors a homologous fimX gene,
the product of which has not been identified. In addition to the
major subunits, the fimbriae also contain the minor 40 kDa
subunit FimD, which serves as the adhesin [68]. Expression of
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Table 1 Bordetella virulence factors
Produced by 
B. pertussis B. parapertussis B. bronchiseptica
Adhesins
Filamentous hemagglutinin + + +
Pertactin + (69 kDa) + (70 kDa) + (68 kDa)
Fimbriaea + + +
Tracheal colonization factor + – –
Serum-resistance protein (Brk)b + ? ?
Toxins
Pertussis toxin + – –
Adenylate cyclase toxin + + +
Dermonecrotic toxin + + +
Tracheal cytotoxin + + +
aIn addition to the major Fim2 and Fim3 subunits, and the minor subunit FimD, B. parapertussis and B. bronchiseptica produce an additional fimbrial subunit, FimA. 
bThe brk genes are present in B. parapertussis and B. bronchiseptica, but it is not known whether they are expressed in these two species.
the fim2 and fim3 genes is regulated by mutations in their
promoter regions, which result in serotype switching [70]. In
particular, a C-rich region may undergo relatively frequent
deletions and insertions. These changes strongly affect the
transcription of the fimbrial genes. As a result, some strains
produce both types of fimbria (serotype 2, 3), some only one
(serotype 2 or 3), or none at all. 
The B. pertussis fimbriae belong to the same family as the
type 1 fimbriae of enterobacteria. Their assembly requires a
periplasmic chaperone, FimB and an outer-membrane usher
protein, FimC. The fim2, fim3 and fimX genes are scattered
along the B. pertussis chromosome, whereas the fimBCD genes
are clustered together with the fha and bvg genes and constitute
a polycistronic operon with fhaC [69]. A pseudogene, fimA, is
located immediately upstream from fimB and may be an
ancestral major structural fimbrial gene from which fim2, fim3
and fimX may have been derived after initial duplication.
Interestingly, fimA is truncated in B. pertussis, whereas it is
complete in B. bronchiseptica and B. parapertussis [7]. 
Like FHA, the major fimbrial subunit can also bind sulfated
glycoconjugates present on the surface of epithelial cells [16].
The minor subunit FimD binds to the VLA-5 integrin of
macrophages. The binding of B. pertussis to VLA-5 upregulates
CR3 integrin expression, thereby increasing the binding of the
organism via FHA to the macrophages [23]. Both the fimbriae
and FHA may thus cooperate in B. pertussis adhesion to, and
perhaps invasion of, alveolar macrophages. Studies in animal
models with defined B. pertussis mutants also suggest that FHA
and fimbriae cooperate in the colonization of the trachea, which
provides some biological significance for the tightly coordinated
expression of these two adhesins. 
Many years ago, it was observed that anti-fimbrial antibodies
in the sera of infected or vaccinated children agglutinate the
bacteria. Therefore, the fimbriae were initially called
agglutinogens. In addition, a correlation was found between
the presence of agglutinating antibodies and protection [51],
which has led to the inclusion of Fim2 and Fim3 as antigens
in some of the new acellular pertussis vaccines. 
Pertactin Pertactin is an outer-membrane protein with an
apparent molecular weight of 69,000. The structural gene, prn,
encodes a protein of 94 kDa which is transported into the
periplasm by a classical signal-peptide dependant secretion
mechanism [9]. It then undergoes proteolytic processing
resulting in the removal of an approximately 30 kDa C-terminal
region. This C-terminal region remains anchored in the outer
membrane and is essential for the secretion of pertactin. It
resembles the C-terminal domains of the precursors of several
secreted proteins from Gram-negative bacteria that are known
to be autotransporters. The best studied example of this family
of proteins is the Neisseria IgA protease [25]. The C-terminal
domains of such proteins are predicted to contain 14
amphipathic β-strands, which may form a β-barrel within the
outer membrane through which the N-terminal moieties of the
proteins may then extrude. The secretion of these proteins does
not therefore require additional specific accessory proteins. In
the case of the IgA protease, the C-terminal domain of the
precursor is cleaved by the autocatalytic activity of the IgA
protease at a precise site resembling the proteolytic cleavage
site within the IgA substrate. However, there is no evidence
that pertactin has protease activity, which suggests that the
processing of pertactin involves other proteases or that pertactin
is not cleaved in physiological conditions. 
The crystal structure of pertactin has been determined 
at 2.5 Å resolution [12]. The protein is a monomer and is
composed of 16 parallel strands that form a β-helix with a 
V-shaped cross-section. Several coils protrude from the β-helix
core. These coils have been associated with the biological
activities of pertactin. An Arg-Gly-Asp sequence involved in
the binding of pertactin to host cells, in particular to integrins
on the surface of epithelial cells, is located adjacent to one of
these coils containing proline-rich repeats (GGXXP)5. The 
C-terminal region of pertactin contains other proline-rich repeats
(PQP)5, such repeats being major protective epitopes of the
protein. 
Pertactin is polymorphic between the various Bordetella
species, and even between different strains within the same species
[44]. B. parapertussis and B. bronchiseptica produce pertactins
with slightly different molecular weights, 70 and 68 kDa,
respectively [35]. These differences are mainly attributed to
differences in the copy numbers of the proline-rich repeats. 
Pertactin was initially discovered during the development
of a veterinary vaccine against B. bronchiseptica [46] and has
been shown to provide protection in animal models. Mutants
deficient in pertactin appear to colonize the mouse respiratory
tract as efficiently as the wild-type parent strains. However,
mutants deficient in both pertactin and FHA are cleared much
more rapidly than the wild-type parents, supporting the notion
that pertactin is involved in bacterial adhesion. Due to its
involvement in adhesion and its protective effect in animal
models, pertactin is also one of the antigens included in some
of the new acellular vaccines [20]. 
The Bordetella serum-resistance protein Brk Brk (for
Bordetella resistance to killing) is responsible for the resistance
of Bordetella to killing by serum [14]. The resistance
mechanism is unknown. However, Brk presents several features
that suggest it is involved in adhesion to host cells. It contains
two Arg-Gly-Asp motifs and two potential binding sites for
sulfated glycoconjugates. Mutant strains that lack Brk are
impaired in binding to eukaryotic cells in vitro and, in murine
models, are less virulent than wild-type parent strains. 
Analyses of the primary structure of the protein suggest
that Brk is derived from a larger, 103 kDa, precursor. Like
pertactin, the Brk precursor contains an approximately 300
residue C-terminal autotranslocator domain with outer-
membrane localization signals. This C-terminal putative
translocator domain has 54.5% of residues identical to those
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in pertactin. It is thus likely that Brk and pertactin use a similar
secretion mechanism. 
The tracheal colonization factor A third protein with a
structure similar to pertactin is the tracheal colonization factor
(Tcf). This protein is produced by B. pertussis, but not by 
B. parapertussis and B. bronchiseptica, and appears to be
specifically involved in the colonization of the trachea [15]. Its
sequence shows several proline-rich regions and, like FHA,
pertactin and Brk, Tcf also contains an Arg-Gly-Asp sequence.
Also, like pertactin and Brk, the C-terminal end of Tcf is
probably an autotransporter domain with a high degree of
sequence similarity to those of pertactin and Brk, again
suggesting a similar secretion mechanism. Tcf is encountered
in two forms, either as a large, cell-associated form, or as a
small, secreted form. 
Toxins
Most B. pertussis toxins are protein toxins (see Table 1), except
for lipopolysaccharide, also called endotoxin, and the tracheal
cytotoxin, which is a fragment of the Bordetella peptidoglycan.
The three major protein toxins are the pertussis toxin, the
adenylate cyclase toxin and the dermonecrotic toxin. 
Pertussis toxin Pertussis toxin (PTX) consists of five dissimilar
subunits, named S1 through S5, according to their decreasing
molecular weights, and are arranged in a 1S1:1S2:1S3:2S4:1S5
stoichiometry [60]. The S2 to S5 subunits form the B moiety
of the toxin, which is responsible for the interaction of the toxin
with the target cell receptors. The S1 subunit, also called the
A protomer, has enzymatic activity that is responsible for most,
if not all, of the biological activities. PTX is therefore a member
of the A-B bacterial protein toxin group. 
S1 has ADP-ribosyltransferase activity using NAD as 
ADP-ribosyl donor and signal transduction, G proteins as 
ADP-ribosyl acceptors. The molecular action of the toxin can
be divided into three major steps, (i) binding of the toxin to 
target cell receptors via the B oligomer, (ii) membrane
translocation of the S1 subunit into the cytosol, and (iii) 
ADP-ribosyltransferase activity by the translocated S1 subunit.
The ADP-ribosylation of the acceptor substrate G proteins,
essentially of the Gi and Go families, results in their inactivation,
and signals that normally regulate intracellular processes, such
as the formation of cAMP, can no longer exert their regulatory
actions. As a consequence, PTX poisoning results in
dysregulation of major metabolic pathways, although the toxin
does not usually kill the target cells. Depending on the cell
type, the toxin may have a variety of physiological effects, such
as histamine sensitization, activation of insulin secretion, or
lymphocytosis, one of the hallmarks of the whooping cough
syndrome [45]. However, this toxin is probably not directly
involved in the typical cough. 
The enzymatic mechanism of PTX has been extensively
studied and the catalytic residues have been identified. 
Glu-129 [3] is a key catalytic residue strictly conserved among
all ADP-ribosylating toxins and enzymes. The carboxyl group
of this residue interacts with the 2'-OH group of the ribose
on NAD [57], which may increase the ionization potential of
the diol, thereby weakening the N-glycoside bond between the
ribose and nicotinamide [37]. This bond can then be cleaved
by the attacking nucleophile, a cysteine in the G protein. A
second catalytic residue, His-35 is thought to activate the
cysteine to increase its nucleophilicity [2]. This residue is less
well conserved among ADP-ribosyltransferases, consistent
with the heterogeneity of acceptor substrates used by the various
ADP-ribosylating toxins. 
The crystal structure of pertussis toxin, defined at a 
3.5 Å resolution, shows that the catalytic Glu-129 and 
His-35 are located next to each other, close to the active site
into which NAD can be modeled [58]. The holotoxin is a
pyramid, with its triangular base formed by the B oligomer.
The S1 subunit is located at the top of the pyramid and inserts
its C-terminal end into the central hole formed by the
juxtaposition of the B oligomer subunits. The triangular base
is formed by one S2-S4 dimer, one S3-S4 dimer and one
connecting S5 subunit. S2 and S3 share approximately 70%
identical residues [38], but have different receptor-binding
specificities [36]. 
All the subunits are exported individually through the inner
membrane, using classical signal peptides. After the removal
of these signal peptides, the subunits assemble into the holotoxin
structure within the periplasm, and the fully assembled toxin
is secreted into the culture medium of B. pertussis. This final
step in toxin secretion requires 9 accessory proteins encoded
by the ptl genes. These proteins are homologous to the
Agrobacterium tumefaciens plasmid transport machinery
encoded by the virB genes [66]. The Bordetella ptl genes are
located immediately downstream from the five structural ptx
genes. They are cotranscribed with the ptx genes, in a single
polycistronic operon. The full set of ptx and ptl genes is also
present in B. bronchiseptica and B. parapertussis [41]. However,
the genes are not expressed in these two species due to an
accumulation of inactivating point mutations, mostly in the
promoter region. 
PTX induces high levels of antibody after infection or
vaccination with classical whole cell vaccine [61], and the
toxin provides full protection against challenge in mouse
models. For this reason, inactivated PTX is the major
protective antigen in all the new acellular vaccines available
today. 
Adenylate cyclase/hemolysin toxin Adenylate cyclase/
hemolysin is a bifunctional protein composed of 1,706 amino
acid residues [18]. This toxin is produced by B. pertussis, 
B. parapertussis and B. bronchiseptica. Via its hemolytic
domain, the toxin delivers its catalytic cyclase domain into
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the cytosol of the target cell. The catalytic domain then
expresses adenylate cyclase activity upon activation by
calmodulin [31]. The catalytic domain is located in the 
N-terminal half of the toxin. The C-terminal half contains
multiple GGXGXDXLX repeats making this toxin a member
of the RTX (for repeats in toxin) toxin family. These repeats
may be the site of binding to calcium, an ion essential for
toxin activity [18]. 
A variety of biochemical and molecular biological studies
have identified several residues, including Trp-242, involved
in the interaction with calmodulin. In addition, Lys-58 and
Lys-65 have been implicated in the catalytic activity of the
enzyme [17]. 
Unlike the other Bordetella virulence factors, adenylate
cyclase is secreted without undergoing proteolytic processing.
Its secretion depends upon three accessory proteins, CyaB,
CyaD and CyaE, the genes of which are located immediately
downstream from the cyclase structural gene [19]. These three
proteins are homologous to the accessory proteins essential for
the secretion of other RTX toxins, such as the alpha-hemolysin
of Escherichia coli. Together, the three proteins form the
secretion apparatus, which belongs to the class of ABC
transporters (for ATP-Binding Cassettes) because ATP binding
is required for secretion. The secretion determinant of the RTX
toxins usually lies within the C-terminal end of the protein and
is not removed upon secretion. 
The adenylate cyclase structural gene is preceded by the
cyaC gene, which is transcribed in the opposite direction from
the structural gene [4]. The cyaC gene product is a protein
necessary for activation of the toxin. It catalyzes the transfer
of a palmitoyl group onto the ε nitrogen of lysine 983 [21].
This palmitoylation is essential for the toxin and hemolytic
activities of adenylate cyclase/hemolysin. 
B. pertussis mutants that do not produce adenylate
cyclase colonize the respiratory tract of infected mice much
less than do the wild-type strains [65]. The toxin has been
shown to be responsible for cell death by apoptosis of the
alveolar macrophages in contact with B. pertussis, which
may be a major way that the organism has evolved to escape
the immune system of the infected host. This may enable it
to colonize the host efficiently. Both enzyme and the
hemolytic activities are required for the induction of
apoptosis [29]. 
Dermonecrotic toxin The dermonecrotic toxin (DNT) was
one of the first B. pertussis toxins to be identified and studied,
but much less is known about this toxin than about the others.
This may be due to the absence of a dramatic effect on
pathogenesis in experimental animal models [63]. However,
the toxin is lethal if injected intravenously into mice, even
at low doses. If injected subcutaneously, it induces skin
lesions. The absence of dramatic effects of the toxin in
infection experiments, comparing isogenic dnt+/– strains, may
be due to the intracellular location of the toxin. Unlike the
other Bordetella toxins, DNT is not secreted and was
therefore initially called endotoxin [6]. Its action in vivo, if
any, may require the lysis of bacterial cells. Alternatively,
the toxin may be secreted at very specific anatomic sites,
in a tightly regulated manner by a mechanism that has not
been identified yet. 
The toxin has a molecular weight of approximately
140,000 and is produced by all three major Bordetella species.
Its molecular action has recently been elucidated. The toxin
deaminates the glutamine 63 residue of the RhoA protein
and changes this glutamine into glutamate. This modification
alters the electrophoretic mobility of the RhoA protein and
decreases its GTPase activity by a factor of 10. This decrease
in GTPase activity blocks RhoA in a permanently active
position, thereby inducing the formation of actin stress fibers,
which are readily detected if the host cells are incubated with
DNT [26]. 
Tracheal cytotoxin The primary structure of tracheal
cytotoxin (TCT) has been determined by fast atom
bombardment mass spectrometry as a 921 Da N-acetyl-
glucosaminyl-1,6-anhydro-N-acetylmuramylalanyl-gamma-
glutamyldiaminopimelylalanine, identical to the Neisseria
gonorrhoeae ciliostatic anhydropeptidoglycan and the slow-
wave sleep-promoting factor [10]. It destroys ciliated epithelial
cells of the respiratory tract, causes an increase in the number
of cells with sparse ciliation and the extrusion of cells from
the epithelial surface. In vitro, TCT inhibits DNA synthesis
in tracheal epithelial cells and induces the production of
intracellular interleukin-1 and of nitric oxide, the most likely
triggers of TCT-mediated cytopathy [24]. The alanyl-gamma-
glutamyldiaminopimelate moiety appears to be the smallest
derivative of TCT with biological activity. However, the alanyl
group may be replaced by other amino acids or blocking
groups. TCT is also produced by the other Bordetella species,
suggesting that it may be of general importance in
bordetellosis. TCT production is not under the control of the
BvgA/S regulatory system. 
Lipopolysaccharide The B. pertussis lipopolysaccharide
(LPS) may act in synergy with other toxins, such as TCT or
pertussis toxin. By itself, it has endotoxin activities, similar
to those of LPS from enteric bacteria. It is lethal in
galactosamine-sensitized mice, and is pyrogenic and
mitogenic in spleen cell cultures. It activates macrophages
and induces the production of tumor necrosis factor [64].
Although all Bordetella species produce LPS, its structure
differs between species, possibly reflecting differences in
the strength of biological activity between  Bordetella species.
B. pertussis contains two LPS classes, LPSI and LPSII [33],
which differ in their polysaccharide moieties. The ratio of
LPSI to LPSII may differ between variants of the same strain
[52]. However, the precise role in pathogenesis of these
structural differences is not clear. 
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Concluding remarks
Our understanding of the molecular mechanisms of B. pertussis
pathogenesis has increased over the past 15 years, since the cloning
of its first virulence gene [38]. This has led to major improvements
in whooping cough vaccines. The original whole cell vaccines may
now be replaced by much less reactogenic acellular vaccines. These
are based on the use of very well defined and properly inactivated
virulence determinants from B. pertussis. These virulence factors
are also the major protective antigens. PTX inactivation has been
achieved by chemical treatment of the protein with formaldehyde
or gluteraldehyde [56], and more elegantly, by genetic inactivation
using site-directed alterations of key amino acid residues in the
active site of the enzymatic subunit S1 [47] and/or of residues of
the B oligomer involved in receptor binding [36]. 
In addition, attenuated B. pertussis has been proposed for use
as a live vaccine that can be administered by the intranasal route
[43]. Interestingly, and in contrast to most other live bacterial
vaccines, genetic attenuation by alteration of the ptx genes does
not decrease the immunogenicity of the organism, but in fact appears
to increase immunogenicity over that of the wild-type strain. This
makes attenuated B. pertussis particularly well suited to intranasal
administration as a single dose mucosal vaccine to protect against
whooping cough. In addition, taking advantage of what is known
about the molecular mechanism of FHA secretion, attenuated B.
pertussis can be engineered such that it produces and secretes
heterologous protective antigens and can therefore be used to protect
simultaneously against pertussis and other infectious diseases. 
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